Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

ASX Announcements

Date Title
31 Jul 2026
Telix H1 2026 Results - Investor Webcast Notification
24 Jul 2026
Change in substantial holding
21 Jul 2026
Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
10 Jul 2026
Notification of cessation of securities - TLX
10 Jul 2026
Notification regarding unquoted securities - TLX
10 Jul 2026
Application for quotation of securities - TLX
08 Jul 2026
Change in substantial holding
03 Jul 2026
Ceasing to be a substantial holder
02 Jul 2026
FDA Alignment to Advance ProstACT Global Phase 3 Trial
01 Jul 2026
Change in substantial holding
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 95

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors